Similarly, in oncogenic MYCN-amplified neuroblastoma, JQ1, a BET-bromo structural domain inhibitor of MYCN, downregulates c-MYC and p53 levels, which in turn downregulate NKG2DL expression and render neuroblastoma cells resistant to NK cell-mediated killing [52]. Here, MYCN is linked to neuroblastoma.